C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes $478,000 Position in Exact Sciences Co. (NASDAQ:EXAS)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, Holdings Channel reports. The firm bought 8,508 shares of the medical research company’s stock, valued at approximately $478,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Chicago Partners Investment Group LLC grew its stake in Exact Sciences by 1.7% during the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after buying an additional 158 shares during the period. Perigon Wealth Management LLC boosted its position in Exact Sciences by 3.2% during the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock worth $474,000 after purchasing an additional 264 shares during the period. Huntington National Bank increased its holdings in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares in the last quarter. CIBC Asset Management Inc raised its position in Exact Sciences by 6.1% in the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock valued at $442,000 after purchasing an additional 371 shares during the period. Finally, Advisors Asset Management Inc. lifted its stake in shares of Exact Sciences by 1.4% during the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock worth $1,952,000 after purchasing an additional 402 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Up 0.5 %

EXAS stock opened at $50.59 on Friday. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62. The firm has a fifty day moving average price of $56.42 and a two-hundred day moving average price of $60.06. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The firm has a market cap of $9.36 billion, a price-to-earnings ratio of -43.24 and a beta of 1.24.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Robert W. Baird lowered their target price on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Bank of America reduced their target price on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Piper Sandler lowered their price target on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Jefferies Financial Group upped their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Citigroup dropped their target price on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $72.76.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.